This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. Have you ever scrolled through your Twitter feed and found something distasteful posted about your company? You may be the

This blog was written by Chuck Wilson, CEO of Unum Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. This is an ongoing saga about finding a new home for my company, Unum Therapeutics. Google tells me that there

Milestone payments are an important risk-sharing component in today’s biopharma deal-making toolbox. As it’s a topic I’ve explored in the past (here, here), it’s an opportune time to revisit the stats for how they have performed recently. These contingent value transfers

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the “From the Trenches” feature of LifeSciVC. “A big asset of VC’s is pattern recognition. It is also often our biggest liability.”  An apt observation tweeted by

This blog was written by Mike Gilman, CEO of Padlock Therapeutics and Atlas EIR, as part of the “From the Trenches” feature of LifeSciVC. Padlock Therapeutics is my second startup, and it’s not nearly as scary as the first one. Not

Biotech venture funding metrics continue at historic highs, highlighting that the robust financing environment in the public markets continues to fuel the private markets as well. Last week the quarterly Thomson Reuters data on venture capital funding came out via

Earlier this week Atlas Venture closed Fund X at $280M, completing our transition to a biotech-only venture firm. After announcing the split of our life science and technology franchises in October 2014 (here), we embarked on the hard work of

This blog was written by Bill Marshall, CEO of miRagen Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. The opportunity to use nucleic acids as therapeutic agents is extremely exciting. Creating drugs that affect protein targets that are

A few weeks ago, Michael Gladstone wrote a blog, here, about infusing young blood into the ‘C’ suite of biotech. I thought he made a number of important points and great suggestions about the topic. Today, I’d like to expand

As anyone following the biotech sector knows, the market for new public offerings has been incredibly strong over the past couple years. And the larger cap stocks in the sector have also outperformed, propelled by product launches and exciting clinical

In a period of surging optimism for our industry, it’s easy to forget that historically most of the therapeutic projects we undertake don’t make it to the market (see the data here if you absolutely have to remind yourself of

A great CEO makes all the difference, and a poor one destroys a ton of value. But recruiting great CEOs is often hard, especially when picking, as is most often the case, from a list of potential first-time CEOs. How